Follow-up study of retinoblastoma consolidation therapy
Part of Cancer, Eyes & vision clinical trials.
This study looks at patients who have received additional cancer treatment after their initial retinoblastoma (eye cancer) therapy and tracks their recovery for at least one year. The research aims to understand how well this follow-up treatment works and what happens to patients over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You received secondary consolidation therapy (additional treatment given after initial cancer treatment)
- At least one year has passed since your treatment ended
- You have complete medical records and data available for review
- Your retinoblastoma was limited to the eye at initial diagnosis (no spread outside the eye or into surrounding tissues)
- You have ongoing follow-up visits and records documenting your progress
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at long-term health outcomes—how patients are doing physically and in daily life—after treatment for retinoblastoma. It may help doctors understand what support or follow-up care could be most helpful after treatment.
This trial looks at care recommendations for children with retinoblastoma (a childhood eye cancer). It may help standardize the best treatment approach for different patterns of tumor spread.
This trial studies whether newer “save-the-eye” treatment plans can control retinoblastoma (eye cancer) while keeping vision as good as possible. It compares different conservative treatment strategies depending on how the tumor looks and where it is.
This Phase 3 study tests whether giving chemotherapy after the eye has been removed can lower the chance of retinoblastoma coming back for children with high-risk disease. You may be screened if your child had one eye affected and meet the staging and treatment history requirements.
This study looks at gene changes in retinoblastoma to understand why some tumors spread outside the eye. It may help find better ways to predict and treat the disease.
This trial tests a high dose of a chemotherapy drug called topotecan given directly into the eye (intravitreal injection) for children with retinoblastoma that has come back or not responded to treatment and has seeds floating in the vitreous. The goal is to save the eye when removal is the only other option.
Hear when a new Retinoblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.